Axinn Represents Thermo Fisher in $7.2 Billion Acquisition of Patheon
May 17, 2017
Axinn is representing Thermo Fisher Scientific Inc. in its $7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The Axinn team consists of John Harkrider and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust
Kisaco Research Trade Secret Legal Protection Conference 2025
Speaking Engagement
Intellectual Property
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
29th Annual IBA Competition Conference
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
MCCA Pathways Conference
Sponsorship
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust